Effects of China’s regulatory onslaught felt in Hong Kong as large IPOs fall by the wayside
- Health care start-up We Doctor and supermarket operator WM Tech among those that have let their IPO applications lapse due to regulatory scrutiny, market weakness
- The value of IPOs dipped to US$6.2 billion in the third quarter – the lowest since the start of the pandemic and behind South Korea for the first time in four years

Hong Kong’s primary-listing market is going through a dry patch in what is normally the busiest time of the year.
“Where the wind blows largely depends on the industry of the IPO-aspirant,” said Justin Tang, head of Asian research at United First Partners in Singapore. “Companies in the consumer tech and real estate related sectors will continue to experience headwinds in the form of the ‘common prosperity’ campaign and regulatory reforms.”
After a stellar first half, the value of IPOs dipped to just US$6.2 billion in the third quarter – the lowest since the start of the pandemic and behind South Korea for the first time in four years. To be sure, 2021 will still likely rank highly in terms of IPO proceeds thanks to the sheer volume of issuance in Hong Kong in the six months. With US$37.7 billion raised so far, this year is on track to be one of the best of the last decade.